News
CCCC
2.560
-6.91%
-0.190
C4 Therapeutics announces annual shareholder meeting webcast
PUBT · 16h ago
Weekly Report: what happened at CCCC last week (0420-0424)?
Weekly Report · 2d ago
Weekly Report: what happened at CCCC last week (0413-0417)?
Weekly Report · 04/20 10:04
Weekly Report: what happened at CCCC last week (0406-0410)?
Weekly Report · 04/13 10:07
Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO
NASDAQ · 04/10 14:00
Jefferies Remains a Buy on C4 Therapeutics (CCCC)
TipRanks · 04/10 12:56
C4 Therapeutics adopts Massachusetts, Delaware federal courts as exclusive forums for securities suits
Reuters · 04/10 11:18
BUZZ-U.S. STOCKS ON THE MOVE-Zscaler, Carlyle, Weight Watchers
Reuters · 04/09 15:51
C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies
Benzinga · 04/09 14:23
BUZZ-U.S. STOCKS ON THE MOVE-Marvell Technology, Tempus AI, Energy Vault
Reuters · 04/09 13:12
Pre-Market Most Active for Apr 9, 2026 : CRWG, CCCC, TSLL, CRWV, SQQQ, TQQQ, NIO, NOK, BABA, BB, SPIR, KOS
NASDAQ · 04/09 12:28
C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates
Seeking Alpha · 04/09 12:11
C4 Therapeutics Enters Collaboration Agreement With Roche
NASDAQ · 04/09 11:52
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, CoreWeave, Kymera
Reuters · 04/09 11:43
C4 Therapeutics Expands Roche Collaboration with New DAC Deal
TipRanks · 04/09 11:32
BUZZ-C4 Therapeutics gains as Roche signs up to $1 bln cancer drug deal
Reuters · 04/09 11:20
C4 Therapeutics publishes corporate presentation outlining cemsidomide, CFT8919 pipeline strategy
Reuters · 04/09 11:12
C4 Therapeutics expands long-term partnership with Roche
TipRanks · 04/09 11:07
C4 Therapeutics Teams Up With Roche On New Cancer Drug Approach, Secures $20M Upfront, Eyes Over $1B In Future Milestones
Benzinga · 04/09 11:03
C4 Therapeutics expands Roche DAC collaboration with $20 million upfront payment
Reuters · 04/09 10:59
More
Webull provides a variety of real-time CCCC stock news. You can receive the latest news about C4 Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).